Depression Clinical Trial
Official title:
Exercise to Prevent Depression and Anxiety in Older Hispanics
| NCT number | NCT02371954 |
| Other study ID # | 20140607 |
| Secondary ID | |
| Status | Completed |
| Phase | N/A |
| First received | |
| Last updated | |
| Start date | September 2013 |
| Est. completion date | August 2018 |
| Verified date | September 2018 |
| Source | University of Miami |
| Contact | n/a |
| Is FDA regulated | No |
| Health authority | |
| Study type | Interventional |
The study is a randomized pilot trial of a health promotion intervention in the prevention of anxiety and depression in older Hispanics.
| Status | Completed |
| Enrollment | 60 |
| Est. completion date | August 2018 |
| Est. primary completion date | August 2018 |
| Accepts healthy volunteers | Accepts Healthy Volunteers |
| Gender | All |
| Age group | 60 Years and older |
| Eligibility |
Inclusion Criteria: 1. Hispanic (self-identified); 2. Age 60+; 3. Minor depression as defined by a primary DSM-IV Axis I diagnosis of minor depressive disorder or subthreshold depression defined as a score = 3 on the Patient Health Questionnaire (PHQ-2), OR subthreshold anxiety as defined as a score = 3 on the Generalized Anxiety Disorder-2 scale (GAD-2); 4. Absence of episodes of major depression and anxiety disorders for past 12 months (as determined by the MINI); 5. Voluntary informed consent for participation in the study by the participant or by the participant's legally designated guardian or conservator; 6. Medical clearance for participation in an exercise program by a physician, physician's assistant, or nurse practitioner; 7. Expect to be resident in Miami for the subsequent 12 months. Exclusion Criteria: 1. Currently residing in a nursing or group home; 2. A terminal physical illness expected to result in the death within one year; 3. A diagnosis of dementia, co-morbid diagnosis of dementia, or significant cognitive impairment as indicated by an MMSE score <24; 4. Presence of any axis 1 psychiatric disorder or substance abuse during preceding 12 months; 5. History of psychiatric disorders other than non-psychotic unipolar major depression or anxiety disorder; 6. High suicide risk, i.e., intent or plan to attempt suicide in the near future (a response of "yes" to questions 3, 4, and/or 5 on the Paykel Questionnaire); 7. Participants taking cognitive enhancing medication or psychotropic medications (e.g. antidepressants); 8. unable to complete 400 m walk test in less than 15 min; 9. if participant heart rate exceeded 170 beats per minute OR systolic blood pressure exceeds 180 during 400 m walk test; 10. chest or leg pain, dyspnea, dizziness, feeling faint, or other significant symptoms while completing 400 m walk test; (i) acute or severe medical illness that would prevent participants from walking at a moderate pace for 45 minutes, three times a week. |
| Country | Name | City | State |
|---|---|---|---|
| United States | Jackson Memorial Mental Health Hospital | Miami | Florida |
| Lead Sponsor | Collaborator |
|---|---|
| University of Miami |
United States,
| Type | Measure | Description | Time frame | Safety issue |
|---|---|---|---|---|
| Primary | Prevention of major depression, generalized anxiety, and social anxiety as measured the Mini International Neuropsychiatric Interview | I will be using the Mini International Neuropsychiatric Interview to test whether the HOLA intervention was successful in preventing participants from getting major depressive disorder, generalized anxiety disorder, and social anxiety disorder. | change from baseline at 16 months | |
| Secondary | Physical functioning as measured by the World Health Organization Disability Assessment Schedule 2.0 (WHO-DAS 2) | I will be measuring the effect the HOLA intervention has on the scores of the Getting Around, Life Activities, and Self-Care subscales of the WHO-DAS 2.0 | change from baseline at 16 months | |
| Secondary | Social functioningas measured by the World Health Organization Disability Assessment Schedule 2.0 (WHO-DAS 2) | I will be measuring the effect the HOLA intervention has on the scores of the Getting Along with People and Participation in Life subscales of the WHO-DAS 2.0 | change from baseline at 16 months | |
| Secondary | Self-efficacy as measured by the General Self-Efficacy Scale | I will be measuring the effect the HOLA intervention has on total scores of the General-Self Efficacy Scale. | change from baseline at 16 months | |
| Secondary | Sleep quality as measured by the Pittsburgh Sleep Quality Index | I will be measuring the effect the HOLA intervention has on the total scores of the Pittsburgh Sleep Quality Index | change from baseline at 16 months | |
| Secondary | Change in depression symptom severity as measured by the Quick Inventory of Depressive Symptomatology - Self Report (QIDS-SR). | I will be measuring the effect the HOLA intervention has on the total scores of the QIDS-SR | change from baseline at 16 months | |
| Secondary | Change in anxiety symptom severity as measured by the Beck Anxiety Inventory (BAI) | I will be measuring the effect the HOLA intervention has on the total scores of the BAI | change from baseline at 16 months |
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Active, not recruiting |
NCT05777044 -
The Effect of Hatha Yoga on Mental Health
|
N/A | |
| Recruiting |
NCT04680611 -
Severe Asthma, MepolizumaB and Affect: SAMBA Study
|
||
| Recruiting |
NCT04977232 -
Adjunctive Game Intervention for Anhedonia in MDD Patients
|
N/A | |
| Recruiting |
NCT04043052 -
Mobile Technologies and Post-stroke Depression
|
N/A | |
| Completed |
NCT04512768 -
Treating Comorbid Insomnia in Transdiagnostic Internet-Delivered Cognitive Behaviour Therapy
|
N/A | |
| Recruiting |
NCT03207828 -
Testing Interventions for Patients With Fibromyalgia and Depression
|
N/A | |
| Completed |
NCT04617015 -
Defining and Treating Depression-related Asthma
|
Early Phase 1 | |
| Recruiting |
NCT06011681 -
The Rapid Diagnosis of MCI and Depression in Patients Ages 60 and Over
|
||
| Completed |
NCT04476446 -
An Expanded Access Protocol for Esketamine Treatment in Participants With Treatment Resistant Depression (TRD) Who do Not Have Other Treatment Alternatives
|
Phase 3 | |
| Recruiting |
NCT02783430 -
Evaluation of the Initial Prescription of Ketamine and Milnacipran in Depression in Patients With a Progressive Disease
|
Phase 2/Phase 3 | |
| Recruiting |
NCT05563805 -
Exploring Virtual Reality Adventure Training Exergaming
|
N/A | |
| Completed |
NCT04598165 -
Mobile WACh NEO: Mobile Solutions for Neonatal Health and Maternal Support
|
N/A | |
| Completed |
NCT03457714 -
Guided Internet Delivered Cognitive-Behaviour Therapy for Persons With Spinal Cord Injury: A Feasibility Trial
|
||
| Recruiting |
NCT05956912 -
Implementing Group Metacognitive Therapy in Cardiac Rehabilitation Services (PATHWAY-Beacons)
|
||
| Completed |
NCT05588622 -
Meru Health Program for Cancer Patients With Depression and Anxiety
|
N/A | |
| Recruiting |
NCT05234476 -
Behavioral Activation Plus Savoring for University Students
|
N/A | |
| Active, not recruiting |
NCT05006976 -
A Naturalistic Trial of Nudging Clinicians in the Norwegian Sickness Absence Clinic. The NSAC Nudge Study
|
N/A | |
| Enrolling by invitation |
NCT03276585 -
Night in Japan Home Sleep Monitoring Study
|
||
| Completed |
NCT03167372 -
Pilot Comparison of N-of-1 Trials of Light Therapy
|
N/A | |
| Terminated |
NCT03275571 -
HIV, Computerized Depression Therapy & Cognition
|
N/A |